Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s three-phase Tigo EI Residential solution has successfully completed mandatory compliance testing in partnership with Východoslovenská distribučná, a.s. (VSD), a Slovak distribution system operator. This certification confirms the compatibility of the Tigo EI Residential solution with local grid requirements and reinforces the Company’s...

Automotive and mobility companies in Asia Pacific are developing advanced digital vehicle platforms and features to stay competitive amid rapid electrification and changing consumer expectations, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2025 ISG Provider Lens® Automotive and Mobility Services and Solutions report for Asia Pacific finds that the market for electric and h...

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025. Record net sales of 2.448 billion USD, representing net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix Double-digit growth in both International markets and the U.S., with strong performance across all product categories, including year-on-year growth of 9.8% for Injectable Aesthetics, 7.7% for Der...

Forrester (Nasdaq: FORR) today announced the full conference agenda for its B2B Summit EMEA 2025, which will take place in London and digitally on 6–8 October 2025. B2B leaders are facing a pivotal moment amidst shifting buyer demands, rising AI influence, economic uncertainty, and evolving global regulations. At B2B Summit EMEA, leaders will learn how to adapt their marketing, sales, and customer success strategies to address these dynamic changes. The event will focus on aligning cross-func...

Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to...